Αρχική World News FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma World News FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma Από Ogkologos - 23 Μαΐου, 2025 682 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cancer Researchers Bring Tools, Experience to COVID-19 Studies 12 Φεβρουαρίου, 2021 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia 30 Ιουλίου, 2021 A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... 21 Σεπτεμβρίου, 2021 EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... 25 Σεπτεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly... Tomorrow is National Prescription Drug Take-Back Day! Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence...